21
Wolf HPO, Brenner KV.
Etomoxir – Wirkung auf Glucose turnover. 22. Jahrestagung der deutschen Diabetes-Gesellschaft, Aachen 1987, Abstract.

22
Wolf HPO, Bliesath H.
Etomoxir – Ein neuer Ansatz in der oralen Diabetestherapie. IX. Internationales Donau-Symposium über Diabetes mellitus, Porto Carras, Halkidiki, Griechenland 1987, Abstrakt.

23
Wolf HPO, Brenner KV.
The effect of a New Oral Antidiabetic Drug (Etomoxir) on Glucose Turnover and Recycling with (1-14C), (3-3H) – Glucose Tracer in Pigs. Diabetologia 30 (1987) No. 7, 598 A.

24
Charlton JA, Thompson CJ, Baylis PH.
The effect of Etomoxir on Blood Concentration of Glucose, beta-Hydroxybutyrate and Acetoacetate in the Streptozotocin-Diabetic Rat. Clin. Sci. 75 (1988) Suppl. 19, 41P.

25
Davies NJ, Olley PM, Wall SR.
Protection of hearts from fatty acid induced ischemic injury. J. Mol. Cell. Cardiol. Abstract 1988.

26
Davies NJ, Olley PM, Lopaschuk GD.
Protection of reperfused ischemic hearts by carnitine acyltransferase inhibition. Annual Meeting of Alberta Heritage Foundation for Medical Research 1988, Abstract.

27
Davies NJ, Olley PM, Lopaschuk GD.
Fatty-Acid Enhanced Myocardial Injury is Reduced by Carnitine Acyltransferase Inhibition During or After Ischemia. Circulation 78 (1988) no. 4, Abstract 262.

28
Gerondaes P, Alberti KGMM, Agius L.
Interactions of inhibitors of carnitine palmitoyltransferase I and fibrates in cultured hepatocytes. Biochem. J. 253 (1988) 169-173.

29
Haupt E, Bliesath H, Hoppe FU, Luehmann R, Wolf HPO, Radtke HW.
Treatment of type 2 diabetic patients (NIDDM) with different dosages of Etomoxir: a placebo controlled DRF-study. Diab. Res. Clin. Pract. 5 (1988) S615.

30
Kozlowski U, Aynsley-Green A, Flecknell PA, Bartlett K.
Ketone body turnover in rats during acute treatment with 2(6(4-chlorophenoxy)hexyl)oxirane-2-carboxylate (Etomoxir). Biochem. Soc. Trans. 16 (1988) 797.